were immunized with irradiated autologous MBP-reactive T cells and monitored for changes in rate of relapse, expanded disability scale score (EDSS) and MRI lesion activity over a period of 24 months. Depletion of MBP-reactive T cells correlated with a reduction (40%) in rate of relapse in RR-MS patients as compared with the pre-treatment rate in the same cohort. However, the reduction in EDSS was minimal in RR-MS patients while the EDSS was slightly increased in SP-MS patients over a period of 24 months
Tovaxin is reporting ( to the financial press anyway) much better results but this is the same scientist and the same process, it's just that instead of being at a University he is now part of a for profit company and they are now a trivalent rather than monovalent vaccine (it targets more than one peptide).
But that having been said it was incorrect of me to attribute tovaxin with only a half success as there are no peer reviewed numbers yet and lay articles such as the one in the previous post should not be used for such things. It might be more successful than the previous vaccine by a long shot. We can hope! My point was nothing helps everyone and I think that is inarguable...